NSE · Healthcare · Drug Manufacturers - General
| Document | Date |
|---|---|
| Investor presentation · Q1 FY27 NGL FINE-CHEM LIMITED – Q1FY27 INVESTOR SUMMARY HEADLINE NUMBERS • Q1FY27 Revenue from Operations: ₹139.16 crores (down 6.75% quarter-on-quarter fro | 2026-08-17 |
| Quarterly results · Q1 FY27 NGL FINE-CHEM LIMITED - Q1 FY2026-27 RESULTS SUMMARY HEADLINE NUMBERS STANDALONE RESULTS (Quarter ended June 30, 2026): • Revenue from Operations: ₹ | 2026-08-12 |
| Annual report FY2026 NGL FINE-CHEM LIMITED – ANNUAL REPORT FY26 SUMMARY HEADLINE NUMBERS • Revenue from operations: ₹500.95 crores (FY26) vs ₹368 crores (FY25) – growth | 2026-07-31 |
| Q4 FY26 earnings call NGL FINE-CHEM LIMITED – Q4 & FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Q4 FY26 Revenue: ₹149.23 crores vs ₹94.97 crores in Q4 FY25 (57% YoY growth; 1 | 2026-05-30 |
| Investor presentation · Q4 FY26 NGL FINE-CHEM LIMITED – Q4 & FY26 INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Revenue: ₹501 crores – up 36.03% Y-o-Y from ₹368.26 crores in FY25 • Q4 F | 2026-05-22 |
| Quarterly results · Q4 FY26 NGL FINE-CHEM LIMITED – SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Revenue from Operations (FY 2025-26): Rs. 50,095.47 lakhs (consolidated | 2026-05-21 |
| Investor presentation NGL FINE-CHEM LIMITED – Q3 & 9M FY26 INVESTOR SUMMARY HEADLINE NUMBERS • Q3 FY26 Revenue from Operations: ₹127.51 crore (up 6.03% Q-o-Q, up 43.11% Y | 2026-02-10 |
| Quarterly results · Q3 FY26 NGL FINE-CHEM LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Consolidated Revenue from Operations (Q3 FY26): Rs 12,750.99 lakhs vs Rs 8,909.88 lakhs | 2026-02-03 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹1.75 / share ex-date Aug 18, 2026 | 2026-08-18 |
| Dividend | ₹1.75 / share ex-date Aug 12, 2025 | 2025-08-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for NGL Fine-Chem Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.